Naomi Litchfield’s passion for Early Access Programs (EAPs) stems from a personal experience - her sister’s life was saved by an early access drug after being diagnosed with four rare cancers. With nearly 20 years of industry experience, Naomi is now the Director Patient Advocacy at Bionical Emas.

In this episode, Naomi and Maya discuss:
• What Early Access Programs are and how they work
• How EAPs provide hope and open doors for patients in need
• The challenges and considerations involved in setting up an EAP

Early Access Resources:
https://bionicalemas.com/resources/johnson-johnson-guide-to-expanded-access/
https://bionicalemas.com/resources/what-is-a-clinical-trial/
https://bionicalemas.com/resources/what-is-an-early-access-program/
https://bionicalemas.com/resources/what-is-real-world-data/

Follow Maya Zlatanova: https://www.linkedin.com/in/mayazlatanova/
Follow Naomi Litchfield: https://www.linkedin.com/in/naomi-litchfield-499670122/

Clinical trials are evolving, but are we innovating fast enough? In this episode Maya sits down with Philip Raeth from Palleos Healthcare to explore how new trial designs can challenge the status quo. From adaptive methodologies to efficiency-driven models, we discuss how rethinking trial structure can help us tackle industry-wide hurdles—not just in patient recruitment and retention, but in trial execution, costs, and outcomes. What does the future of clinical trials look like? Tune in as we brainstorm new possibilities.

Follow Philip Raeth: https://www.linkedin.com/in/philip-raeth-51911114/
Follow Maya Zlatanova: https://www.linkedin.com/in/mayazlatanova/

Paul Simms is the CEO of Impatient Health and a trailblazing voice in the life sciences industry. Paul is on a mission to push the boundaries of pharma. He works with innovators and early adopters to inject “mutation pressure” into the status quo, ensuring bold ideas and creative solutions make their way into the market. Drawing on his experience as a speaker, event organizer, and consultant, Paul discusses how pharma can evolve to truly align with patients’ needs. Together, with Maya they explore the intersection of innovation, behavioral science, and systemic transformation in healthcare.

What You’ll Learn:
- Why Paul believes the pharma industry is still in its infancy and how it can grow.
- What “mutation pressure” means and how it can drive innovation in pharma.
- The critical role of patient engagement and behavioral science in improving healthcare outcomes.
- How Paul’s work with major pharma companies has shaped his views on the future of the industry.
- Practical lessons from other industries, including fashion and tech, that pharma can adopt.